59603-1 |
Alpha hydroxyalprazolam |
MCnt |
Meconium |
Pt |
Qn |
Confirm |
|
ACTIVE |
Alpha hydroxyalprazolam [Mass/mass] in Meconium by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
10 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59603-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
A-OH Alpraz Mec Cfm-mCnt |
|
|
|
N |
|
Alfa; Alpha hydroxy alprazolam; Alprozolam metabolite; A-OH Alpraz; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; Hydroxy alprazolam; Hydroxyalpraz; LC/MS/MS; Mass content; Mec; OH-Alpraz; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59604-9 |
Alpha hydroxyalprazolam |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
Alpha hydroxyalprazolam [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59604-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
A-OH Alpraz SerPl Cfm-mCnc |
|
|
|
N |
|
Alfa; Alpha hydroxy alprazolam; Alprozolam metabolite; A-OH Alpraz; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; Hydroxy alprazolam; Hydroxyalpraz; LC/MS/MS; Level; Mass concentration; OH-Alpraz; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59605-6 |
Alpha hydroxyalprazolam |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
Alpha hydroxyalprazolam [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59605-6 |
|
|
|
|
Both |
|
|
|
0 |
A-OH Alpraz Tiss-mCnt |
|
|
|
N |
|
Alfa; Alpha hydroxy alprazolam; Alprozolam metabolite; A-OH Alpraz; DRUG/TOXICOLOGY; Drugs; Hydroxy alprazolam; Hydroxyalpraz; Mass content; OH-Alpraz; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59606-4 |
Alpha hydroxyalprazolam |
MCnt |
Tiss |
Pt |
Qn |
Confirm |
|
ACTIVE |
Alpha hydroxyalprazolam [Mass/mass] in Tissue by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59606-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
A-OH Alpraz Tiss Cfm-mCnt |
|
|
|
N |
|
Alfa; Alpha hydroxy alprazolam; Alprozolam metabolite; A-OH Alpraz; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; Hydroxy alprazolam; Hydroxyalpraz; LC/MS/MS; Mass content; OH-Alpraz; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59607-2 |
ALPRAZolam |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
ALPRAZolam [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59607-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Alpraz Bld Cfm-mCnc |
|
|
|
N |
|
Blood; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Niravam; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood; Xanax |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59608-0 |
ALPRAZolam |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
ALPRAZolam [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59608-0 |
|
|
|
|
Both |
|
|
|
0 |
Alpraz Fld-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Level; Mass concentration; Niravam; Point in time; QNT; Quan; Quant; Quantitative; Random; Xanax |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59609-8 |
ALPRAZolam |
MCnc |
Body fld |
Pt |
Qn |
Confirm |
|
ACTIVE |
ALPRAZolam [Mass/volume] in Body fluid by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59609-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Alpraz Fld Cfm-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; GCMS; LC/MS/MS; Level; Mass concentration; Niravam; Point in time; QNT; Quan; Quant; Quantitative; Random; Xanax |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
5961-8 |
Coagulation tissue factor induced.factor substitution^20M post incubation.37 deg c after addition of normal plasma |
Time |
PPP |
Pt |
Qn |
Tilt tube |
|
DEPRECATED |
Deprecated Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --20M post incubation with normal plasma |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
5961-8 |
|
Tilt tube |
|
|
|
|
|
|
0 |
Deprecated PT PPP Qn |
|
|
|
|
|
@37c; 20M p Inc; After; Coag; Control; degree; Fac; Fact; Hematology; Heme; Mixing studies; Plas; Platelet poor plasma; Point in time; Pro time; Prothrombin time; Protime; PST; PT; PT correction study; PT immediate mix; PT incubated mix; QNT; Quan; Quant; Quantitative; Random |
2.36 |
1.0d |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
59610-6 |
ALPRAZolam |
MCnt |
Meconium |
Pt |
Qn |
Confirm |
|
ACTIVE |
ALPRAZolam [Mass/mass] in Meconium by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59610-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Alpraz Mec Cfm-mCnt |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass content; Mec; Niravam; Point in time; QNT; Quan; Quant; Quantitative; Random; Xanax |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59611-4 |
ALPRAZolam |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
ALPRAZolam [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59611-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Alpraz SerPl Cfm-mCnc |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Niravam; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Xanax |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59612-2 |
ALPRAZolam |
MCnt |
Stool |
Pt |
Qn |
Confirm |
|
ACTIVE |
ALPRAZolam [Mass/mass] in Stool by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59612-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Alpraz Stl Cfm-mCnt |
|
|
|
N |
|
Bowel movement; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Faecal; Faeces; Fecal; Feces; GCMS; LC/MS/MS; Mass content; Niravam; Point in time; QNT; Quan; Quant; Quantitative; Random; Stl; Stool = Fecal; Xanax |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59613-0 |
ALPRAZolam |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
ALPRAZolam [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59613-0 |
|
|
|
|
Both |
|
|
|
0 |
Alpraz Tiss-mCnt |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Mass content; Niravam; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified; Xanax |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59614-8 |
ALPRAZolam |
MCnt |
Tiss |
Pt |
Qn |
Confirm |
|
ACTIVE |
ALPRAZolam [Mass/mass] in Tissue by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59614-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Alpraz Tiss Cfm-mCnt |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass content; Niravam; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified; Xanax |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59615-5 |
ALPRAZolam |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
ALPRAZolam [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59615-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Alpraz Ur Cfm-mCnc |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Niravam; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn; Xanax |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59616-3 |
Benzoylecgonine |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
Benzoylecgonine [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
Cocaine Degradation Product ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59616-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
BZE SerPl Cfm-mCnc |
|
|
|
N |
|
BEC; BEG; Benz; Benzoylec; BZE; Cfm; CNFR; CNFRM; Cocaine degradation production; Cocaine metabolite; Conf; Confirmation; Confirmatory; Crack metabolite; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59617-1 |
chlordiazePOXIDE |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
chlordiazePOXIDE [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59617-1 |
|
|
|
|
Both |
|
|
|
0 |
Chlordiazep Bld-mCnc |
|
|
|
N |
|
Blood; Chlordiaz; Chlordiaze; Chlordiazep; DRUG/TOXICOLOGY; Drugs; Level; Librium; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59618-9 |
chlordiazePOXIDE |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
chlordiazePOXIDE [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59618-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Chlordiazep Bld Cfm-mCnc |
|
|
|
N |
|
Blood; Cfm; Chlordiaz; Chlordiaze; Chlordiazep; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Librium; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59619-7 |
chlordiazePOXIDE |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
chlordiazePOXIDE [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59619-7 |
|
|
|
|
Both |
|
|
|
0 |
Chlordiazep Fld-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Chlordiaz; Chlordiaze; Chlordiazep; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Level; Librium; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
5962-6 |
Coagulation tissue factor induced.factor substitution^immediately after addition of normal plasma |
Time |
PPP |
Pt |
Qn |
Tilt tube |
|
DEPRECATED |
Deprecated Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
5962-6 |
|
Tilt tube |
|
|
|
|
|
|
0 |
Deprecated PT imm NP PPP Qn |
|
|
|
|
|
Coag; Control; Fac; Fact; Hematology; Heme; imm NP; Immediatedly after 1:1 addition of; Mixing studies; Plas; Platelet poor plasma; Point in time; Pro time; Prothrombin time; Protime; PT; PT correction study; PT immediate mix; PT incubated mix; QNT; Quan; Quant; Quantitative; Random |
2.36 |
1.0d |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
59620-5 |
chlordiazePOXIDE |
MCnc |
Body fld |
Pt |
Qn |
Confirm |
|
ACTIVE |
chlordiazePOXIDE [Mass/volume] in Body fluid by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59620-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Chlordiazep Fld Cfm-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cfm; Chlordiaz; Chlordiaze; Chlordiazep; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; GCMS; LC/MS/MS; Level; Librium; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59621-3 |
chlordiazePOXIDE |
MCnt |
Meconium |
Pt |
Qn |
Confirm |
|
ACTIVE |
chlordiazePOXIDE [Mass/mass] in Meconium by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
20 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59621-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Chlordiazep Mec Cfm-mCnt |
|
|
|
N |
|
Cfm; Chlordiaz; Chlordiaze; Chlordiazep; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Librium; Mass content; Mec; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59622-1 |
chlordiazePOXIDE |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
chlordiazePOXIDE [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
20 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59622-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Chlordiazep SerPl Cfm-mCnc |
|
|
|
N |
|
Cfm; Chlordiaz; Chlordiaze; Chlordiazep; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Librium; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59623-9 |
chlordiazePOXIDE |
MCnt |
Stool |
Pt |
Qn |
Confirm |
|
ACTIVE |
chlordiazePOXIDE [Mass/mass] in Stool by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
20 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59623-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Chlordiazep Stl Cfm-mCnt |
|
|
|
N |
|
Bowel movement; Cfm; Chlordiaz; Chlordiaze; Chlordiazep; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Faecal; Faeces; Fecal; Feces; GCMS; LC/MS/MS; Librium; Mass content; Point in time; QNT; Quan; Quant; Quantitative; Random; Stl; Stool = Fecal |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59624-7 |
chlordiazePOXIDE |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
chlordiazePOXIDE [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
20 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59624-7 |
|
|
|
|
Both |
|
|
|
0 |
Chlordiazep Tiss-mCnt |
|
|
|
N |
|
Chlordiaz; Chlordiaze; Chlordiazep; DRUG/TOXICOLOGY; Drugs; Librium; Mass content; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59625-4 |
chlordiazePOXIDE |
MCnt |
Tiss |
Pt |
Qn |
Confirm |
|
ACTIVE |
chlordiazePOXIDE [Mass/mass] in Tissue by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
20 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59625-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Chlordiazep Tiss Cfm-mCnt |
|
|
|
N |
|
Cfm; Chlordiaz; Chlordiaze; Chlordiazep; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Librium; Mass content; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |